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Short summary: 
In a Botswana national meningitis survey, we observed a high 2013-2014 incidence of 
cryptococcal meningitis, particularly in men in their 4
th
-5
th
 decade, highlighting the need 
to target populations at high risk for advanced HIV and adopt HIV differentiated care 
models.   
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ABSTRACT 
 
Background: Botswana has a well-developed antiretroviral therapy (ART) program 
which serves as a regional model. With wide ART availability, the burden of advanced 
HIV and associated opportunistic infections would be expected to decline. We performed 
a nationwide surveillance study to determine the national incidence of cryptococcal 
meningitis, and describe characteristics of cases 2000-2014 and temporal trends at two 
national referral hospitals.  
 
Methods: Cerebrospinal fluid data from all 37 laboratories performing meningitis 
diagnostics in Botswana were collected 2000-2014 to identify cases of cryptococcal 
meningitis. Basic demographic and laboratory data were recorded. Complete national 
data from 2013-2014 were used to calculate national incidence using UNAIDS 
population estimates. Temporal trends in cases were derived from national referral 
centers 2004-2014.  
 
Results: 5296 episodes of cryptococcal meningitis were observed in 4702 individuals; 
60.6% were male, and median age was 36 years. Overall 2013-2014 incidence was 17.8 
cases/100,000 person-years (95%CI 16.6 – 19.2). In the HIV-infected population, 
incidence was 96.8 cases/100,000 person-years (95%CI 90.0 – 104.0); male 
predominance was seen across CD4 strata. At national referral hospitals, cases decreased 
2007-2009 but stabilized 2010-2014.  
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Conclusions: Despite excellent ART coverage in Botswana, there is still a substantial 
burden of advanced HIV, with 2013-2014 incidence of cryptococcal meningitis 
comparable to pre-ART era rates in South Africa. Our findings suggest a key population 
of individuals, often men, are developing advanced disease and associated opportunistic 
infections due to a failure to effectively engage in care, highlighting the need for 
differentiated care models. 
 
Key words: Cryptococcal meningitis, incidence, HIV, Botswana, sub-Saharan Africa 
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INTRODUCTION 
Botswana was the first country in Africa to establish a national ART program and began 
providing treatment free-of-charge to its HIV-infected population in early 2002 [1]. 
National HIV care guidelines in 2012 recommended a CD4 T-cell threshold of <350 
cells/μL for ART initiation, up from <200 cells/μL in 2008 [2, 3], and recent population 
level data suggest that, in rural regions, the program is close to achieving “90-90-90” 
targets set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) [4]. Despite 
the success of the national ART program, Botswana, a country of approximately two 
million people, still has high incidence of new HIV infections in certain populations and 
an HIV prevalence among the highest in the world, with an estimated adult HIV 
prevalence of 25% in 2014 [5, 6]. 
 
In sub-Saharan Africa as a whole, as in Botswana, although millions now access life-
saving antiretroviral therapy (ART), overall HIV prevalence is still not declining and 
ART is initiated at low CD4 T-cell counts in a majority of HIV-infected individuals [7-9], 
resulting in a large population at substantial risk of opportunistic disease and with high 
rates of mortality [10]. Care default and treatment failure further increase the size of this 
high-risk population, with pooled observational cohort data from African settings 
suggesting only 65% of patients starting first-line ART remain in care at 36 months and 
virological failure and acquired ART resistance frequently observed [11-13]. Movement 
toward an HIV “test and treat” strategy in sub-Saharan Africa, which was adopted in 
Botswana in June 2016, will necessitate streamlining models of care to quickly expand 
treatment programs, which has the potential of leaving vulnerable patients further behind.  
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Cryptococcal meningitis (CM) is a severe fungal infection primarily seen in individuals 
with defective cell-mediated immunity [14], with the vast majority of cases occurring in 
the context of advanced HIV infection [15]. CM typically affects individuals with CD4 
cell counts <100 cells/µL, and is now frequently described following late ART initiation 
and ART default, as well as in ART naïve individuals [16-18]. As countries move toward 
expanded HIV treatment programs, CM serves as an important indicator disease for 
national programs. An understanding of advanced HIV disease burden and temporal 
trends in sub-populations will guide program delivery and differentiated models of HIV 
care targeting groups most at risk for delayed HIV diagnosis, ART initiation, and care 
default, with the associated morbidity and mortality and high transmission risks.  
 
We collected laboratory records from all facilities in Botswana that perform meningitis 
diagnostics and UNAIDS country-level HIV prevalence estimates to determine the 2013-
2014 national incidence rate of cryptococcal meningitis, describe characteristics of CM 
cases over a 15-year period, and define temporal trends in cases diagnosed at the two 
national referral hospitals.  
 
METHODS 
Study design 
The Botswana National Meningitis Survey was a 15-year retrospective review of routine 
cerebrospinal fluid (CSF) laboratory records to determine the etiologies of meningitis in 
Botswana and temporal trends with maturation of the local HIV epidemic.  The study was 
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conducted in collaboration with the Botswana Ministry of Health (MoH) and the National 
Health Laboratory. Institutional review board (IRB) approval was obtained from the 
University of Botswana, University of Pennsylvania, University of Washington, Health 
Research Development Council (Botswana Ministry of Health), and at hospitals with 
independent IRB committees (Letsholathebe Memorial Hospital, Mahalapye Hospital, 
Nyangabwe Referral Hospital, Princess Marina Hospital, Scottish Livingstone Hospital, 
and Sekgoma Memorial Hospital).  
 
Participating laboratories and CSF data collection 
Thirty-seven laboratories are registered by the Botswana National Health Laboratory to 
perform cerebrospinal fluid (CSF) testing for the diagnosis of cryptococcal meningitis by 
India ink stain, fungal culture, and/or cryptococcal antigen (CrAg) testing, including two 
national referral hospitals, seven district hospitals (six medical, one psychiatric), and 28 
primary, private, mining, and military hospital-based, clinic-based, or standalone 
laboratories. Facilities were visited by the study team for collection of meningitis-related 
laboratory data. Most visits took place between February 2015 and May 2015. All 
available CSF records from January 1, 2000 through January 1, 2015 were located at 
facilities. Records were scanned on a password-protected study laptop, then numbered 
and entered into a REDCap database. To ensure data accuracy during transcription of 
paper-based records into the REDCap database, a minimum of two study team members 
reviewed each entry and discrepancies were adjudicated through consensus.  
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In addition to paper records, a majority of hospital-based laboratories maintain records on 
a government-financed electronic medical record (EMR), Integrated Patient Management 
System (IPMS). At facilities with IPMS, clinical data is entered directly into IPMS with 
laboratory books used to keep records during internet downtime or entered both in 
laboratory notebooks and IPMS. IPMS was queried centrally at the MoH to obtain all 
Botswana CSF-related electronic laboratory records and HIV-related data (CD4 T-cell 
count nearest to the date of cryptococcal meningitis diagnosis). Paper-based records from 
the REDCap database were merged with IPMS records using Stata (version 12, College 
Station, TX), matching by date, testing location, and patient identifiers (name, age, 
gender), and duplicate entries removed. Three hospitals used additional EMR platforms 
for limited periods during the study period. Electronic records from these EMR platforms 
were also queried using CSF-related search terms and this data entered into the REDCap 
database.  
 
Population denominator data 
The UNAIDS Spectrum model version 5.41 was used to determine population numbers 
[19], national HIV prevalence, new HIV infections, and the distribution of CD4 count. 
Two module sets were activated for this projection.  The demographic set included 
DEMPROJ – to estimate the population by age and sex, and FAMPLAN – to estimate the 
impact of family planning services on population size. The HIV set included AIM – to 
estimate the impact of HIV, GOALS – to estimate the funding needed to achieve the 
national HIV response targets, and RNM – to estimate the costs of implementing the 
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national HIV program. Model inputs were derived from published country reports, 
strategic plans, costing studies, programmatic data, and expert opinion [20]. 
 
Patients and case definition 
Records were obtained of any patient who received a lumbar puncture (LP) for CSF 
analysis without an age cut-off. In Botswana, routine diagnostic CSF testing for 
cryptococcal meningitis includes India ink stain and fungal culture. CSF testing for CrAg 
was performed using latex agglutination tests by several centers and routinely at referral 
hospital laboratories. The cryptococcal lateral flow assay was not available in Botswana 
during the study period.  
 
A “case” (or episode) of cryptococcal meningitis was defined as CSF with positive India 
ink stain, Cryptococcus culture, and/or positive CSF CrAg. As CSF analysis may have 
been repeated on patients receiving multiple LPs for lowering of intracranial pressure or 
other indications during an admission, all positive CSF samples for a unique patient 
within a single documented hospitalization (or in the absence of admission dates, within a 
≤ 14-day window of any previous CSF sample) were considered part of the same “case.” 
 
Data analysis 
Data were analyzed using Stata (version 12, College Station, TX). Cases of cryptococcal 
meningitis in Botswana were enumerated using the case definition. The number of cases, 
recurrent cases, patient age and gender, and month and season of diagnosis were 
described using frequencies, percentage or median and interquartile range (IQR), as 
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appropriate. It was not possible to calculate national incidence rates over the full 15-year 
study period, as records prior to 2013 were partially complete. Complete CSF laboratory 
data from all laboratories were obtained during 2013 and 2014 calendar years. For this 
2013-2014 national data, UNAIDS Spectrum model HIV estimates were used as a 
population denominator to determine cryptococcal meningitis incidence rate in person-
years of observation with 95% confidence intervals (95%CI) derived using a Poisson 
distribution. Incidence was estimated by gender and ordinal age categories as well as by 
CD4 T-cell count category stratified by gender in individuals ≥15-years old.  
 
The two national referral hospitals (Princess Marina Hospital and Nyangabwe Referral 
Hospital) adopted IPMS in 2004 and also maintained paper-based records, yielding a 
complete dataset for the 11-year period 2004 to 2014. At these two hospitals, annual 
cases diagnosed over this 11-year period were displayed graphically in relation to the 
“treatment gap” (UNAIDS-estimated HIV-infected population ≥15 years of age minus 
population receiving ART) and median CD4 cell count at ART initiation.  
 
RESULTS 
15-year cryptococcal meningitis data 
We identified 5296 unique cases of cryptococcal meningitis in 4702 individuals from 
2000-2014 (Table 1). Of these individuals, 90.3% (4248/4702) experienced a single 
episode, 7.7% (360/4702) two episodes, 1.0% (48/4702) three episodes, and 1.0% 
(46/4702) four or more episodes of disease. Median age at diagnosis was 36 years (IQR 
30-43 years) (Figure 1) and more cases were diagnosed in males than females (60.6% 
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males versus 39.4% females). There was no evidence of seasonality. Case numbers did 
not differ with respect to month or season at diagnosis.  
 
2013-2014 incidence of cryptococcal meningitis 
National incidence of diagnosed cryptococcal meningitis 2013-2014 was 17.8 
cases/100,000 person-years (95%CI 16.6 – 19.2 cases/100,000 person-years), with higher 
incidence observed in males than in females (22.0 cases/100,000 person-years in males 
[95%CI 20.1 – 24.1 cases/100,000 person-years] versus 13.7 cases/100,000 person-years 
[95%CI 12.1 – 15.3 cases/100,000 person-years] in females) (Table 2, Figure 2A-B). 
Peak incidence was observed in 40-44 year olds, with an earlier peak among females (30-
34 years) and a later peak among males (40-44 years) mirroring national age trends in 
HIV prevalence.  
 
In the HIV-infected population, overall incidence was 96.8 cases/100,000 person-years 
(95%CI 90.0 – 104.0 cases/100,000 person-years), or 135.4 cases/100,000 person-years 
(95%CI 123.4 – 148.3 cases/100,000 person-years) in males and 66.3 cases/100,000 
person-years (95%CI 58.9 – 74.4 cases/100,000 person-years) in females. Incidence rate 
was relatively uniform across adult age categories, peaking in the 4
th
 through 5
th
 decade 
of life (Figure 2C). Although the absolute number of CM cases in children was relatively 
low, incidence was comparatively high in the two youngest age categories (0-4 years and 
5-9 years), declining in the 10-14 year age group, then increasing to adult levels in the 
adolescent category (15-19 years). Note that the high incidence in the 0-4 year age 
category may be spuriously high due to an underestimation of the denominator in the 
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UNAIDS figures and low overall numbers in both the numerator and denominator 
categories. Incidence increased markedly with declining CD4 T-cell count strata. In those 
with CD4 T-cell counts <50 cells/μL, a nearly 2% annual incidence was observed, of 
1854 cases/100,000 person-years (95%CI 1680.5 – 2042.0 cases/100,000 person-years), 
with higher incidence in males than females across CD4 count strata (Figure 3).  
 
Referral hospital temporal trends 
At the two national referral hospital laboratories, processing 60% of CSF samples, the 
number of cases of cryptococcal meningitis cases decreased between 2004 and 2014, 
with a marked decrease 2007-2009 but only a modest decline in 2010-2014, despite a 
shift in national ART guidelines recommending ART initiation at a higher CD4 count 
(<350 cells/μL in 2012 guidelines versus <200 cells/μL in 2008 guidelines) [2, 3]. Figure 
4A shows cases of cryptococcal meningitis diagnosed at the referral hospitals, with total 
HIV-infected population in Botswana ≥15 years of age and population on ART over time. 
Over this period, the median CD4 count at ART initiation increased from 2007-2011 but 
remained stable 2012-2014 (Figure 4B), with similar trends observed in the total 
population of HIV-infected individuals with CD4 counts <200 cells/μL (Figure 4C).  
 
DISCUSSION 
These are the first robust national cryptococcal meningitis incidence estimates from a 
resource-limited country. Collection of complete records from all laboratories in 
Botswana performing CSF testing allowed us to accurately estimate 2013-2014 national 
incidence rates, revealing a high incidence of cryptococcal meningitis in Botswana in the 
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context of the highest population antiretroviral therapy coverage in Africa. The 2013-
2014 Botswana national cryptococcal meningitis incidence is almost identical to the pre-
ART era (2002-2004) laboratory surveillance-based incidence estimates from Gauteng 
Province, South Africa (17.8 cases/100,000 person-years versus 15.6 cases/100,000 
person-years, respectively), a period when estimated adult (15-49 years) HIV prevalence 
in South Africa was 21.5% [21, 22]. Limited to only HIV-infected populations, 2013-
2014 Botswana incidence of 96.8 cases/100,000 person-years is again comparable to 
South African incidence estimates from the pre-ART era (95 cases/100,000 person-years), 
and greater than 100-fold higher than the 2009 estimated United States HIV-associated 
cryptococcal meningitis rate of 7.7 cases/1,000,000 person-years [15]. 
 
The rate of decline in cryptococcal meningitis cases diagnosed at referral center 
laboratories has stagnated in recent years, despite national data showing high rates of 
HIV testing, ART uptake, and viral suppression [4]. These findings reflect a number of 
factors, including high ongoing national HIV prevalence, only modest improvements in 
median CD4 T-cell counts at ART initiation in recent years, from 191 cells/μL (IQR 115 
– 239 cells/μL) in 2010 to 258 cells/μL (IQR 147 – 337 μL) in 2013 despite a shift in 
national guidelines promoting earlier therapy [1-3, 23], and high annual incidence of new 
HIV infection estimated at 1.5-2.5% in adults [24]. Importantly, these findings suggest 
that, despite a decade and a half of free and widely available HIV testing and treatment 
services in Botswana, a population of vulnerable individuals are not being effectively 
reached, engaged, or retained by current testing and treatment services. This key 
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population is now the main driver of HIV-related morbidity and mortality, and likely to 
be maintaining the high ongoing incidence of HIV acquisition in this setting.  
 
With stabilizing or rising adult HIV prevalence in Botswana and the African region, 
eliminating the remaining treatment gap and advanced HIV-disease will require 
innovative solutions to effectively reach key populations who are being missed by current 
testing and treatment models, diagnose and treat early asymptomatic infection, and 
promote lifelong engagement with treatment services. Updated 2016 guidelines in 
Botswana, in line with 2015 World Health Organization guidelines, now recommend the 
“test and treat” strategy of ART at any CD4 count for people living with HIV [25, 26]. 
This represents a critical step toward reducing advanced HIV disease and opportunistic 
infections like cryptococcal meningitis and tuberculosis. However, the latest Botswana 
AIDS Indicator Survey data estimated 30% of the population aged 10-64 years had never 
undergone HIV testing in 2013 and ART coverage [24], at about 250,000 HIV-infected 
individuals by 2015 [23], needs to expand by 100,000, which will put a strain on existing 
services [27]. Similar scale-up will likely be even more disruptive throughout the rest of 
Africa, where the number of people receiving ART needs to double to cover all HIV-
infected individuals [28]. To avoid leaving vulnerable individuals behind, differentiated 
care models should be considered to streamline care for populations with well-controlled 
disease and focus more intensive resources on those with higher need who are now 
driving the epidemic.  
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Our study provides important insights into the characteristics of individuals presenting 
with advanced HIV and cryptococcal meningitis in Botswana. We found peak incidence 
of disease in adults in the 4
th
 and 5
th
 decade of life, suggesting a need to better engage 
young, working-age adults through work- or community-based care models that 
minimize lost opportunity costs. Strikingly, we observed a greater than two-fold higher 
incidence of disease in HIV-infected males than HIV-infected females. Although this did 
not completely correct when the analysis was stratified by CD4 count, perhaps in part 
reflecting a true gender-related biological predisposition to cryptococcal disease for 
which the pathogenesis is incompletely understood [29, 30], it highlights the high 
numbers of men presenting late to care or failing to engage with testing and treatment 
services. Young women may also have greater likelihood of HIV diagnosis and routine 
care with pre-natal, post-natal, and contraceptive services.   
  
This study had several important limitations. First, these estimates likely represent the 
lowest range of true cryptococcal meningitis incidence rates in Botswana due to the 
limitations of deriving incidence estimates from laboratory-based surveillance, including 
missing individuals who died before seeking medical care or who sought care but went 
undiagnosed due to misdiagnosis, stock out of lumbar puncture equipment or laboratory 
reagents, or lumbar puncture refusal [31]. Although we applied a rigorous approach to 
data collection and estimated incidence only for 2013-2014 when we believed laboratory 
data to be complete, missed case ascertainment may also have led to spuriously low 
incidence estimates. A small number of individuals may have sought care from 
neighboring countries, but this is not likely to have significantly impacted our findings. 
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Over 85% of cases in the IPMS dataset had a Botswana national identification number 
and the vast majority of the remainder could be identified as citizens using available 
identifying data. Uncertainty in UNAIDS Spectrum model denominator estimates could 
lead to either overestimation or underestimation, although figures are based on the most 
robust and contemporary data available and are validated against reliable national census 
and HIV population prevalence survey results [24]. Secondly, as a laboratory-based 
surveillance study we did not have national data on ART treatment history and were 
unable to stratify incidence based on ART status. However, single-center data from 
Princess Marina Hospital indicates that 51% of cryptococcal meningitis patients are now 
presenting on ART [32], in keeping with other regional data [16, 17]. Thirdly, we were 
unable to ascertain outcomes, although 2012-2014 data from Princess Marina Hospital 
showed a 10-week cryptococcal meningitis mortality of 50% and 1-year mortality of 65% 
[33]. The competing risk of high mortality could explain, in part, the relatively low 
observed relapse rate. Finally, we were unable to evaluate temporal trends in 
cryptococcal meningitis outside of the two referral hospitals due to incomplete records, 
which might differ from urban settings where referral centers are located. However, as 
almost two-thirds of cases were diagnosed at referral centers, this provides meaningful 
information regarding national trends.   
 
In summary, we provide evidence for a high ongoing burden of advanced HIV disease in 
Botswana, a country with a mature ART program and the highest population ART 
coverage in Africa. Our findings highlight a need not only to adopt disease-specific 
measures to reduce cryptococcal meningitis, such as CrAg screening in patients with 
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advanced disease [34-36], but the broader need to engage and link key populations to 
care who are being missed with current strategies. Adoption of HIV test and treat could 
substantially reduce advanced HIV disease but must be coupled with paradigm shifts in 
testing, care linkage, and ART delivery such as differentiated care models and 
decentralized testing and HIV care delivery. 
 
  
Cryptococcal meningitis in Botswana 
 18 
ACKNOWLEDGMENTS 
We thank the Afya Bora Consortium, Diakanyo Moalosi at the Botswana Ministry of 
Health for her assistance with querying IPMS records, Freedom Ernest at the Botswana 
National Health Laboratory for assistance with arranging laboratory visits, as well as 
multiple health facility and laboratory personnel at Athlone Hospital, Bobonong Primary 
Hospital, Deborah Retief Memorial Hospital, Ghanzi Primary Hospital, GoodHope 
Primary Hospital, Gumare Primary Hospital, Gweta Primary Hospital, Hukuntsi Primary 
Hospital, Kasane Primary Hospital, Lethlakane Primary Hospital, Lobatse Mental 
Hospital, Mahalapye Hospital, Masunga Primary Hospital, Letsholathebe Memorial 
Hospital, Mmadinare Primary Hospital, Nyangabwe Referral Hospital, Palapye Primary 
Hospital, Princess Marina Hospital, Rakops Primary Hospital, Scottish Livingstone 
Hospital, Sefhare Primary Hospital, Selibe-Phikwe Hospital, Sekgoma Memorial 
Hospital, Thamaga Primary Hospital, Tshabong Primary Hospital, Tutume Primary 
Hospital, Extension 2 Clinic, Charles Hill Clinic, Area W Clinic, Thebephatshwa Air 
Base, Bamalete Lutheran Hospital, Kanye Seventh-Day Adventist Hospital, Jwaneng 
Mine Hospital, Diagnofirm Medical Center, Gaborone Private Hospital Lancet 
Laboratory, Tati River Clinic Laboratory,  and Bokamoso Hospital Laboratory for their 
assistance. Individually, we would like to thank Thato Mogapi, Bothwell Muviiwa, Kago 
Gofamodimo, Olefile Bickie Bagwasi, Tlotlo Bogatsu, David Lubasi, Nobley Chunda, H 
Farrar Otieno, Felix C Banda, Joy Mangilazi, Koabetswe Ramalepa, Modisaotsile Emdee 
Ramaologa, Caroline Kekana, Stephen Motlhagodi, Ephraim Dambe, Keoratile 
Ntshambiwa, George Simwanza, Phillip Joseph, Cynthia M Kuate, Steven Tsima, Jenny 
Tommy, Patrick Rancholo, Finini Biyangidiki, Asini Mosango, Zein Sasikwa, Jacqueline 
Cryptococcal meningitis in Botswana 
 19 
Kasambala, Keontse Nyamadzabo, Keteng Mphoyakgosi, Olivier Betu, Frank Nyimbili, 
Moemedi Banda, Leabaneng Molomo, and Gabriel Malomo, among others who provided 
assistance to our study team during laboratory visits.  
 
FUNDING AND CONFLICTS OF INTEREST 
This work was supported by the Penn Center for AIDS Research, a National Institutes of 
Health (NIH)–funded program (grant number P30 AI 045008 to JNJ) as well as the NIH 
Office of AIDS Research and Centers for Disease Control and Prevention (CDC) / 
President’s Emergency Plan for AIDS Relief (PEPFAR) grant support (grant number 
U91HA06801B to MWT). The REDCap platform is supported by grants UL1TR000423 
from NCRR/NIH. JNJ has received funding support from Gilead Sciences Europe, 
outside of the submitted work. EAW has received scholarship support from Bristol-
Myers-Squibb Pharmaceuticals, outside of the submitted work. All other authors have no 
relevant disclosures.  
 
 
 
  
Cryptococcal meningitis in Botswana 
 20 
REFERENCES 
1. Farahani M, Vable A, Lebelonyane R, et al. Outcomes of the Botswana 
national HIV/AIDS treatment programme from 2002 to 2010: a 
longitudinal analysis. Lancet Glob Health 2014; 2(1): e44-50. 
2. Botswana Ministry of Health. 2012 Botswana national HIV & AIDS 
treatment guidelines. Available 
at: https://hivpolicywatch.org/duremaps/data/guidelines/BotswanaA
RTguidelines2012.pdf. Accessed 28 March 2017. 
3. Botswana Ministry of Health. Botswana national HIV/AIDS treatment 
guidelines: 2008 version. Available at: 
http://www.moh.gov.bw/Publications/HIVAIDS TREATMENT 
GUIDELINES.pdf. Accessed 28 March 2017. 
4. Gaolathe T, Wirth KE, Holme MP, et al. Botswana's progress toward 
achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and 
virological suppression goals: a population-based survey. Lancet HIV 
2016; 3(5): e221-30. 
5. Karim SA. Is the UNAIDS target sufficient for HIV control in Botswana? 
Lancet HIV 2016; 3(5): e195-6. 
6. UNAIDS. HIV and AIDS estimates - Botswana. Available at: 
http://www.unaids.org/en/regionscountries/countries/botswana/. 
Accessed 28 March 2017. 
7. Wang H, Wolock TM, Carter A, et al. Estimates of global, regional, and 
national incidence, prevalence, and mortality of HIV, 1980-2015: the 
Global Burden of Disease Study 2015. Lancet HIV 2016; 3(8): e361-87. 
8. Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC. Trends in 
CD4 count at presentation to care and treatment initiation in sub-
Saharan Africa, 2002-2013: a meta-analysis. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of 
America 2015; 60(7): 1120-7. 
9. Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of 
combination antiretroviral therapy in low-, middle-, and high-income 
countries. Journal of acquired immune deficiency syndromes 2014; 
65(1): e8-16. 
10. Brennan AT, Long L, Useem J, Garrison L, Fox MP. Mortality in the First 3 
Months on Antiretroviral Therapy Among HIV-Positive Adults in Low- 
and Middle-income Countries: A Meta-analysis. Journal of acquired 
immune deficiency syndromes 2016; 73(1): 1-10. 
11. Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy 
in Low- and Middle-Income Countries: Systematic Review and Meta-
analysis 2008-2013. Journal of acquired immune deficiency syndromes 
2015; 69(1): 98-108. 
12. Boender TS, Hoenderboom BM, Sigaloff KC, et al. Pretreatment HIV drug 
resistance increases regimen switches in sub-Saharan Africa. Clinical 
infectious diseases : an official publication of the Infectious Diseases 
Society of America 2015; 61(11): 1749-58. 
Cryptococcal meningitis in Botswana 
 21 
13. Group TS. Global epidemiology of drug resistance after failure of WHO 
recommended first-line regimens for adult HIV-1 infection: a 
multicentre retrospective cohort study. Lancet Infect Dis 2016; 16(5): 
565-75. 
14. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. Aids 
2007; 21(16): 2119-29. 
15. Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology 
of cryptococcal meningitis in the US: 1997-2009. PloS one 2013; 8(2): 
e56269. 
16. Scriven JE, Lalloo DG, Meintjes G. Changing epidemiology of HIV-
associated cryptococcosis in sub-Saharan Africa. Lancet Infect Dis 2016; 
16(8): 891-2. 
17. Rhein J, Morawski BM, Hullsiek KH, et al. Efficacy of adjunctive 
sertraline for the treatment of HIV-associated cryptococcal meningitis: 
an open-label dose-ranging study. Lancet Infect Dis 2016; 16(7): 809-18. 
18. Jarvis JN, Harrison TS. Forgotten but not gone: HIV-associated 
cryptococcal meningitis. Lancet Infect Dis 2016; 16(7): 756-8. 
19. Avenir Health. Spectrum. Available at: 
http://www.avenirhealth.org/software-spectrum.php. Accessed 28 
March 2017. 
20. Avalos A, Phillips H, Jefferis K. Botswana investment case: Investment 
towards effective HIV prevention, health system strengthening and the 
end of AIDS. Presented at: Botswana Ministry of Health. Gaborone, 
Botswana, 2016. 
21. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based 
surveillance for cryptococcosis in an antiretroviral-naive South African 
province with a high HIV seroprevalence. Aids 2006; 20(17): 2199-206. 
22. UNAIDS. 2004 report on the global AIDS epidemic. Available 
at: http://files.unaids.org/en/media/unaids/contentassets/documents
/unaidspublication/2004/GAR2004_en.pdf. Accessed 28 March 2017. 
23. Farahani M, Price N, El-Halabi S, et al. Trends and determinants of 
survival for over 200 000 patients on antiretroviral treatment in the 
Botswana National Program: 2002-2013. Aids 2016; 30(3): 477-85. 
24. Botswana Ministry of Health. Botswana AIDS impact survey IV 2013. 
Available at: 
http://botswana.microdatahub.com/index.php/catalog/14. Accessed 
28 March 2017. 
25. Botswana Ministry of Health. 2016 integrated HIV clinical care 
guidelines. Available at: 
http://www.moh.gov.bw/Publications/Handbook_HIV_treatment_guide
lines.pdf. Accessed 28 March 2017. 
26. World Health Organization. Guideline on when to start antiretroviral 
therapy and on pre-exposure prophylaxis for HIV. Available at: 
http://apps.who.int/iris/bitstream/10665/186275/1/978924150956
5_eng.pdf?ua=1. Accessed 28 March 2017. 
Cryptococcal meningitis in Botswana 
 22 
27. McGovern S, Phillips H, Mosime W, et al. Test results of testing cost-yield 
prioritization model for test and treat in Botswana. Presented at: 21st 
International AIDS Conference. Durban, South Africa, 2016. 
28. World Health Organization. Global health sector response to HIV, 2000-
2015: Focus on innovations in Africa. Available at: 
http://apps.who.int/iris/bitstream/10665/198065/1/978924150982
4_eng.pdf. Accessed 28 March 2017. 
29. McClelland EE, Hobbs LM, Rivera J, et al. The role of host gender in the 
pathogenesis of Cryptococcus neoformans infections. PloS one 2013; 
8(5): e63632. 
30. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the 
CNS in immunocompetent hosts: influence of cryptococcal variety on 
clinical manifestations and outcome. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 1995; 
20(3): 611-6. 
31. Thakur KT, Mateyo K, Hachaambwa L, et al. Lumbar puncture refusal in 
sub-Saharan Africa: A call for further understanding and intervention. 
Neurology 2015; 84(19): 1988-90. 
32. Jarvis JN, Leeme T, Chofle, et al. High dose liposomal amphotericin for 
HIV-infected cryptococcal meningitis. Presented at: CROI 2017. Seattle, 
WA, 2017. 
33. Leeme TB, Patel RK, Azzo C, et al.  Mortality due to HIV-associated 
cryptococcal meningitis in Botswana in the ART era. Presented at: CROI 
2017. Seattle, WA, 2017. 
34. Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing 
Cryptococcosis-Shifting the Paradigm in the Era of Highly Active 
Antiretroviral Therapy. Curr Trop Med Rep 2015; 2(2): 81-9. 
35. Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis 
screening and community-based early adherence support in people 
with advanced HIV infection starting antiretroviral therapy in Tanzania 
and Zambia: an open-label, randomised controlled trial. Lancet 2015. 
36. Lechiile K, Mitchell HK, Mulenga F, et al. Prevalence of advanced HIV 
disease and cryptococcal infection in Gaborone, Botswana. Presented 
at: CROI 2017. Seattle, WA, 2017. 
 
 
 
  
Cryptococcal meningitis in Botswana 
 23 
Figures 
 
Figure 1. Age distribution of cryptococcal meningitis cases in Botswana, 2000-2014.  
 
Figure 2. Incidence of cryptococcal meningitis in Botswana by age category, 2013-
2014. 2A) Overall incidence and interquartile range; 2B) Incidence by gender (males 
solid bars and females striped bars); 2C) Incidence in HIV-infected population.  
 
Figure 3. Incidence of cryptococcal meningitis in Botswana in HIV-infected 
population by CD4 strata, 2013-2014. 3A) Overall incidence; 3B) Incidence by 
gender (males black lines, females grey lines).  
 
Figure 4. Trends in diagnosed cases of cryptococcal meningitis at the 2 national 
referral hospitals in Botswana, 2004-2014. 4A) Cases diagnosed at referral hospitals 
(thick black line) and treatment gap in adults (≥15 years) [shaded grey area]; 4B) 
UNAIDS estimate of median CD4 count at antiretroviral therapy initiation in 
Botswana; 4C) UNAID estimate of total number of HIV-infected individuals with 
CD4 cell counts <200 cells/μL.  
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Tables 
 
Table 1. Description of cryptococcal meningitis cases in Botswana, 2000-2014.  
Total Cryptococcal Meningitis Episodes 5296 
Total Cryptococcal Meningitis Patients 4702 
 Single episode 4248 90.3% 
 Two episodes 360 7.7% 
 Three episodes 48 1.0% 
 Four or more episodes 46 1.0% 
     
Variable Value Number with 
data 
Result (N, %)* 
Age
**
  (Median, IQR) 4056 36 years 30 – 43 years 
Sex
**
  Male 4407 2670 60.6% 
 Female  1737 39.4% 
Site
†
 Tertiary 5296 3161 59.7% 
 Primary/Secondary   2135 40.3% 
Month
†
 January 5296 430 8.1% 
 February  442 8.4% 
 March  481 9.1% 
 April  398 7.5% 
 May  432 8.2% 
 June  418 7.9% 
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 July  449 8.4% 
 August  490 9.3% 
 September  435 8.2% 
 October  423 8.0% 
 November  456 8.6% 
 December  442 8.4% 
Season
†
 Summer (Nov-Jan) 5296 1328 25.1% 
 Autumn (Feb-Apr)  1321 24.9% 
 Winter (May-Jul)  1299 24.5% 
 Spring (Aug-Oct)  1348 25.5% 
*Unless otherwise indicated 
**De-duplicated to represent individual patients rather than cryptococcal meningitis episodes. 
†Data from all cryptococcal meningitis episodes including relapses.  
IQR = interquartile range 
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Table 2. National incidence of cryptococcal meningitis in Botswana, 2013-2014.  
Strata Category Case Number Person-years Incidence 
(per 100,000 
PYO) 
95% Confidence 
Interval (per 
100,000 PYO) 
Overall Incidence 
All - 755 4,231,095 17.8 16.6 – 19.2 
Sex Male 466 2,115,031 22.0 20.1 – 24.1 
 Female 289 2,116,063 13.7 12.1 – 15.3 
Age 
(years)  0-4 10 475,589 2.1 1.0 – 3.9 
  5-9 4 467,021 0.9 0.2 – 2.2 
  10-14  5 458,710 1.1 0.4 – 2.5 
  15-19  20 457,334 4.4 2.7 – 6.8 
  20-24  37 450,494 8.2 5.8 – 11.3 
  25-29  79 424,031 18.6 14.8 – 23.2 
  30-34  156 371,214 42.0 35.7 – 49.2 
  35-39  138 295,495 46.7 39.2 – 55.2 
  40-44  141 212,707 66.3 55.8 – 78.2 
  45-49  76 158,636 47.9 37.8 – 60.0 
  50-54  40 125,781 31.8 22.7 – 43.3 
  55-59  27 107,792 25.1 16.5 – 36.4 
  60-64  10 83,350 12.0 5.8 – 22.1 
  65-69  4 55,035 7.3 2.0 – 18.6 
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  70-74  3 42,068 7.1 1.5 – 20.8 
  75+  3 45,839 6.5 1.4 – 19.1 
HIV infected (Any CD4 Count) 
All - 755 779,997 96.8 90.0 – 104.0 
Sex Male 466 344,120 135.4 123.4 – 148.3 
 Female 289 435,877 66.3 58.9 – 74.4 
CD4 cell count <200 cells/µL
*
 
All - 690 241,445 285.8 264.9 – 307.9 
Sex Male 432 119,120 362.7 329.3 – 398.5 
 Female 259 122,325 211.7 186.7 – 239.2 
CD4 cell count <100 cells/µL
*
 
All - 590 74,845 788.3 726.0 – 854.6 
Sex Male  370 39,304 941.4 847.9 – 1042.4 
 Female 221 35,541 621.8 542.5 – 709.4 
CD4 cell count <50 cells/µL
*
 
All - 415 22,376 1854.7 1680.5 – 2042.0 
Sex Male 260 11,846 2194.8 1936.1 – 2478.5 
 Female 156 10,530 1481.5 1258.1 – 1733.1 
*Restricted to individuals aged 15 years old or greater. 
PYO = person years of observation 
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